Boehringer Ingelheim and ZEISS Medical Technology have announced a strategic collaboration aimed at developing predictive analytics for the early detection of eye diseases, with the goal of preventing vision loss in individuals with serious eye conditions. This partnership combines their expertise in ophthalmological technology, data analytics, algorithms, and the development of treatments for detecting and treating retinal diseases before irreversible vision loss occurs.

Currently, over 300 million people worldwide are at risk of losing their eyesight due to retinal diseases, a number expected to increase due to aging populations and healthcare disparities. Undiagnosed and untreated retinal diseases can significantly impact people’s lives, leading to isolation, loss of independence, depression, and reduced quality of life, often with late diagnoses or no available treatments.

The collaboration will focus on identifying early-stage markers of retinal diseases using ZEISS Medical Technology’s cloud-connected devices and AI-assisted image analysis. This will form the basis for clinical studies to develop personalized and precise treatments for early chronic retinal disease stages and improve early detection and prediction capabilities to preserve vision through new treatment approaches.

ZEISS’s longstanding expertise in optics and its digital leadership play a pivotal role in their medical ecosystem, enabling digitally connected workflows that leverage data aggregation, automation, and AI analytics to drive new discoveries. Boehringer Ingelheim, with its deep understanding of disease biology, is dedicated to bringing about a paradigm shift in retinal health through early detection and intervention, aiming to achieve significant improvements for patients. Their focus areas include preserving vascular function, targeting inflammation, and neuroprotection in addressing retinal conditions.

Article written by Boehrnger Ingelheim|Image by Pexels



Boehringer Ingelheim